Artwork

Content provided by Evaluating Biopharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Evaluating Biopharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Episode: 3 - Cell and Gene Therapy: Managing the ‘Build or Buy’ Decision

22:36
 
Distribuie
 

Manage episode 346453420 series 3394448
Content provided by Evaluating Biopharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Evaluating Biopharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Dave Backer, founder of DB Biologics and former chief commercial officer at Oxford Biomedica, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the complex business and technological decisions companies face when navigating supply chain issues in the cell and gene therapy (CGT) market. Today’s companies must decide whether to build new facilities and produce their own supplies, continue buying from CDMOs despite excessive lead times, or choose a hybrid model.

In this episode, Backer outlines the critical factors every CGT company should consider before venturing into manufacturing. He talks about why companies must think of plasma, lentivirus, and autologous cell therapy lines as separate entities, the value of developing solid partnerships with CDMOs, and how a hybrid model can protect intellectual property while still maximizing productivity.
Links from this episode:
Evaluating Biopharma
Oxford Biomedica
Black Diamond Networks

Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.

  continue reading

16 episoade

Artwork
iconDistribuie
 
Manage episode 346453420 series 3394448
Content provided by Evaluating Biopharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Evaluating Biopharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Dave Backer, founder of DB Biologics and former chief commercial officer at Oxford Biomedica, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the complex business and technological decisions companies face when navigating supply chain issues in the cell and gene therapy (CGT) market. Today’s companies must decide whether to build new facilities and produce their own supplies, continue buying from CDMOs despite excessive lead times, or choose a hybrid model.

In this episode, Backer outlines the critical factors every CGT company should consider before venturing into manufacturing. He talks about why companies must think of plasma, lentivirus, and autologous cell therapy lines as separate entities, the value of developing solid partnerships with CDMOs, and how a hybrid model can protect intellectual property while still maximizing productivity.
Links from this episode:
Evaluating Biopharma
Oxford Biomedica
Black Diamond Networks

Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.

  continue reading

16 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință